# A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients

> **NCT04193527** · PHASE3 · COMPLETED · sponsor: **GE Healthcare** · enrollment: 172 (actual)

## Conditions studied

- Parkinsonian Syndrome
- Parkinson Disease(PD)
- Multiple System Atrophy (MSA)
- Progressive Supranuclear Palsy (PSP)
- Essential Tremor

## Interventions

- **DRUG:** DaTSCAN™ Ioflupane (123I) Injection

## Key facts

- **NCT ID:** NCT04193527
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-28
- **Primary completion:** 2021-12-20
- **Final completion:** 2021-12-20
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2023-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04193527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04193527, "A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04193527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*